Blog
Valuable TargetsAdvanced Tech.
Recent blog posts
Bemremeran Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Bemremeran Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Bemremeran: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Leritrelvir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Leritrelvir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Leritrelvir: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Narlumosbart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Narlumosbart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Narlumosbart: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Anaprazole Sodium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Anaprazole Sodium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Anaprazole Sodium: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Tafolecimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Tafolecimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Tafolecimab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Taurolidine/Heparin sodium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Taurolidine/Heparin sodium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Taurolidine/Heparin sodium: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Bexagliflozin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Bexagliflozin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Bexagliflozin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
R21/Matrix-M Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
R21/Matrix-M Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
R21/Matrix-M: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Fezolinetant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Fezolinetant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Fezolinetant: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Retagliptin Phosphate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Retagliptin Phosphate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Retagliptin Phosphate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Albuterol/Budesonide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Albuterol/Budesonide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Albuterol/Budesonide: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Adebrelimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Adebrelimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Adebrelimab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →